SeaStar Medical announces CEO Eric Schlorff's presentation at Biotech Showcase and investor meetings during J.P. Morgan Healthcare Conference.
Quiver AI Summary
SeaStar Medical Holding Corporation, a healthcare company focused on treating critically ill patients with organ failure, announced that CEO Eric Schlorff will present at the Biotech Showcase 2026 on January 13, 2026, in San Francisco. The presentation will be streamed live and available for replay on the company’s website for 30 days. Additionally, SeaStar's management will engage with investors at the J.P. Morgan Healthcare Conference from January 12-14, 2026. SeaStar's QUELIMMUNE therapy, approved by the FDA in 2024, targets life-threatening acute kidney injury in critically ill pediatric patients and is based on their patented Selective Cytopheretic Device technology. The company is also conducting a pivotal trial for its therapy in adult patients with acute kidney injury.
Potential Positives
- SeaStar Medical's CEO will present at the Biotech Showcase 2026 Investor Conference, which could enhance the company's visibility and attract potential investors.
- The QUELIMMUNE (SCD-PED) therapy is the only FDA-approved product for life-threatening acute kidney injury in critically ill pediatric patients, highlighting the company's unique position in the market.
- The Selective Cytopheretic Device (SCD) therapy has received Breakthrough Device Designation from the FDA for six indications, indicating strong regulatory support and potential for rapid commercialization.
- The company is conducting a pivotal trial in adult patients, addressing a significant unmet need in the healthcare market, which may lead to further growth and recognition within the industry.
Potential Negatives
- The company's reliance on a single product (QUELIMMUNE) for a rare condition could pose risks to revenue stability if it does not gain wider acceptance or if competitors emerge.
- The presentation at the Biotech Showcase comes at a time when investor confidence in biotech companies may be waning, potentially affecting investor interest and market perception.
- The announcement makes no mention of financial performance or projected sales, which could raise concerns among investors regarding the company's current fiscal health.
FAQ
What is SeaStar Medical Holding Corporation?
SeaStar Medical is a healthcare company focused on innovative treatments for critically ill patients facing organ failure.
When will Eric Schlorff present at the Biotech Showcase 2026?
Eric Schlorff will present on January 13, 2026, at 3:00 p.m. Pacific Standard Time.
Where can I access the live presentation?
The live presentation will be available on SeaStar Medical's website.
What is QUELIMMUNE (SCD-PED) therapy?
QUELIMMUNE is SeaStar Medical's FDA-approved therapy for life-threatening acute kidney injury in critically ill pediatric patients.
How can I contact SeaStar Medical Investor Relations?
You can reach SeaStar Medical Investor Relations at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ICU Insider Trading Activity
$ICU insiders have traded $ICU stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ICU stock by insiders over the last 6 months:
- HEEL KENNETH VAN has made 2 purchases buying 35,000 shares for an estimated $30,812 and 0 sales.
- KEVIN CHUNG (Chief Medical Officer) purchased 10,000 shares for an estimated $8,000
- MICHAEL MESSINGER (Chief Financial Officer) purchased 14,500 shares for an estimated $5,098
- JENNIFER A BAIRD purchased 4,200 shares for an estimated $987
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ICU Hedge Fund Activity
We have seen 10 institutional investors add shares of $ICU stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 319,879 shares (+556.3%) to their portfolio in Q3 2025, for an estimated $182,331
- GEODE CAPITAL MANAGEMENT, LLC added 190,094 shares (+276.2%) to their portfolio in Q3 2025, for an estimated $108,353
- MILLENNIUM MANAGEMENT LLC added 179,673 shares (+inf%) to their portfolio in Q3 2025, for an estimated $102,413
- UBS GROUP AG removed 81,100 shares (-88.6%) from their portfolio in Q3 2025, for an estimated $46,226
- VIRTU FINANCIAL LLC removed 37,832 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $21,564
- TORONTO DOMINION BANK added 25,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $14,249
- TYCHE WEALTH PARTNERS LLC removed 20,000 shares (-53.1%) from their portfolio in Q3 2025, for an estimated $11,399
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at the Biotech Showcase 2026 Investor Conference at the Hilton Union Square, San Francisco, CA, on January 13, 2026, at 3:00 p.m. Pacific Standard Time.
The live presentation will be available on the Company's website and can be accessed here . A replay of the presentation will be available at approximately 6:00 p.m. Pacific Standard Time on January 13, 2026, and can be accessed here . The replay will be available for up to 30 days following its posting.
Additionally, SeaStar Medical’s management team will be meeting with investors in San Francisco during the 44 th Annual J.P. Morgan Healthcare Conference from January 12-14, 2026.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. The QUELIMMUNE (SCD-PED) therapy was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X .
Contact:
SeaStar Investor Relations:
[email protected]
